Filing Flows › Cumberland Pharmaceuticals (CPIX) › Q1 2026 › vs Q4 2025
Cumberland Pharmaceuticals (CPIX) Q1 2026 vs Q4 2025 (quarter over quarter)
Cumberland Pharmaceuticals's revenue fell $4.5M (-33%) from $13.7M in Q4 2025 to $9.1M in Q1 2026.
Cumberland Pharmaceuticals, Q1 2026: revenue $9.1M (-22% year over year), operating margin -34.3%, net loss $3.3M, operating cash flow $387K. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $9.1M | $13.7M | −$4.5M | -33% |
| Net loss | $3.3M | $1.4M | $1.9M | +130% |
| Costs & expenses | $12.4M | $15.1M | −$2.7M | -18% |
| Operating costs | $12.3M | $15.0M | −$2.8M | -19% |
| Interest & other, net | $154K | $34K | $120K | +350% |
| Income tax | $4K | $23K | −$19K | -83% |
| Cost of revenue | $1.9M | $2.2M | −$307K | -14% |
| Research & development | $1.5M | $1.5M | −$91K | -6% |
| Sales & marketing | $5.1M | $6.2M | −$1.1M | -18% |
| General & admin | $2.6M | $4.0M | −$1.5M | -37% |
| Other operating costs | $1.2M | $1.0M | $236K | +23% |
| Operating cash sources | $3.7M | $1.4M | $2.2M | +157% |
| Depreciation & amortization | $1.3M | $1.0M | $234K | +22% |
| Share-based compensation | $107K | $172K | −$65K | -38% |
| Working capital & other | $2.3M | $218K | $2.1M | +953% |
| Net loss absorbed | $3.3M | $1.4M | $1.9M | +130% |
| Operating cash flow | $387K | $3K | $384K | 128× |
Questions
How much did Cumberland Pharmaceuticals's revenue grow quarter over quarter in Q1 2026?
Cumberland Pharmaceuticals's revenue fell $4.5M (-33%) from $13.7M in Q4 2025 to $9.1M in Q1 2026.